Janus Henderson Group PLC reduced its position in CG Oncology, Inc. (NASDAQ:CGON - Free Report) by 2.7% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 1,485,843 shares of the company's stock after selling 40,691 shares during the period. Janus Henderson Group PLC owned 1.95% of CG Oncology worth $42,618,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in CGON. Foresite Capital Management VI LLC bought a new stake in shares of CG Oncology in the fourth quarter valued at approximately $63,712,000. Marshall Wace LLP grew its stake in CG Oncology by 18,836.0% in the 4th quarter. Marshall Wace LLP now owns 1,458,072 shares of the company's stock valued at $41,818,000 after buying an additional 1,450,372 shares in the last quarter. Wellington Management Group LLP raised its holdings in CG Oncology by 274.4% during the 4th quarter. Wellington Management Group LLP now owns 1,910,470 shares of the company's stock valued at $54,792,000 after acquiring an additional 1,400,251 shares during the period. Acorn Capital Advisors LLC purchased a new stake in shares of CG Oncology during the fourth quarter worth $32,451,000. Finally, Decheng Capital LLC lifted its position in shares of CG Oncology by 16.3% during the fourth quarter. Decheng Capital LLC now owns 6,371,669 shares of the company's stock worth $182,739,000 after acquiring an additional 892,859 shares in the last quarter. 26.56% of the stock is currently owned by institutional investors.
CG Oncology Stock Performance
Shares of CG Oncology stock opened at $24.18 on Wednesday. The stock has a market capitalization of $1.84 billion, a price-to-earnings ratio of -17.03 and a beta of 1.08. The company has a fifty day moving average of $23.48 and a 200-day moving average of $28.36. CG Oncology, Inc. has a 52-week low of $14.80 and a 52-week high of $40.47.
CG Oncology (NASDAQ:CGON - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.09). CG Oncology had a negative net margin of 10,642.98% and a negative return on equity of 18.97%. On average, equities research analysts forecast that CG Oncology, Inc. will post -1.31 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Several equities analysts have recently weighed in on the company. JPMorgan Chase & Co. started coverage on CG Oncology in a research report on Friday, May 2nd. They issued an "overweight" rating and a $41.00 price target for the company. Morgan Stanley reaffirmed an "overweight" rating and set a $55.00 target price on shares of CG Oncology in a report on Friday, March 7th. HC Wainwright reissued a "buy" rating and issued a $75.00 price target on shares of CG Oncology in a report on Monday, April 28th. Royal Bank of Canada boosted their price objective on shares of CG Oncology from $66.00 to $68.00 and gave the company an "outperform" rating in a research note on Tuesday, April 29th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $75.00 target price on shares of CG Oncology in a report on Monday, April 28th. One investment analyst has rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $58.56.
View Our Latest Stock Report on CGON
Insider Buying and Selling at CG Oncology
In other news, Director Leonard E. Post sold 1,000 shares of CG Oncology stock in a transaction that occurred on Monday, April 28th. The stock was sold at an average price of $30.76, for a total value of $30,760.00. The sale was disclosed in a document filed with the SEC, which is available through this link. 7.40% of the stock is currently owned by corporate insiders.
CG Oncology Company Profile
(
Free Report)
CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.
See Also
Want to see what other hedge funds are holding CGON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CG Oncology, Inc. (NASDAQ:CGON - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider CG Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CG Oncology wasn't on the list.
While CG Oncology currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
